BioCentury | Nov 19, 2020
Finance

Seed financing in hand, VastBiome mines the genes of gut microbes

The founders of VastBiome have parlayed a Texas Medical Center Biodesign fellowship into support from the Illumina Accelerator, and now a $4.5 million seed round co-led by Merck Global Health Innovation Fund. Launched in Houston...
BioCentury | Nov 2, 2020
Politics, Policy & Law

‘Vaccinationalism’ could keep poor countries unprotected from pandemic

As the U.S. and Europe prepare mass vaccination plans for 2021, billions of people living in low- and middle-income countries could have to wait until 2024 for the chance to be protected from COVID-19,...
BioCentury | Jul 22, 2020
Finance

Shonan iPark venture consortium seeks to boost bets on Japanese biotechs

A consortium established by Japanese life sciences accelerator Shonan iPark aims to grow the funding base for local biotechs by bolstering connections between investors. The Japan VC Consortium, launched Tuesday, will promote collaboration between Japanese...
BioCentury | May 14, 2020
Management Tracks

Former GSK exec Slaoui to lead Trump’s ‘Warp Speed’ vaccine initiative

BIO President and CEO Jim Greenwood welcomed the appointment Wednesday of vaccine veteran Moncef Slaoui as head of the Trump administration’s Operation Warp Speed initiative, which is intended to fast-track COVID-19 vaccine development. Slaoui, now...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BioCentury | Apr 7, 2020
Product Development

Doing the right thing isn’t enough. The public needs to know

Now is not the time for the industry to be doing good behind closed doors. The biopharma industry has broken its norms in an all-hands-on-deck campaign to arrest the coronavirus crisis. It is shelving projects...
BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
BioCentury | Aug 31, 2019
Product Development

Digital dollars: financing for digital health

...others Mkt No Series A $2.5 AstraZeneca, Genentech Inc. , Merck & Co. Merck Global Health Innovations...
...Biomarker & tool Type II diabetes Mkt No IPO $408.5 Merck & Co. Merck Global Health Innovations...
...Series C $20.5 AbbVie Inc. (NASDAQ:ABBV), Biogen Inc. (NASDAQ:BIIB), undisclosed others Hikma Ventures, Merck Global Health Innovations...
BioCentury | Jul 26, 2019
Emerging Company Profile

Limbix: A virtual treatment for the reality of depression

Limbix is using virtual reality to treat mental health conditions, starting with adolescent depression, where it could offer an alternative to medicating kids and the long wait lists for therapists. The company launched in 2016...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
Items per page:
1 - 10 of 94
BioCentury | Nov 19, 2020
Finance

Seed financing in hand, VastBiome mines the genes of gut microbes

The founders of VastBiome have parlayed a Texas Medical Center Biodesign fellowship into support from the Illumina Accelerator, and now a $4.5 million seed round co-led by Merck Global Health Innovation Fund. Launched in Houston...
BioCentury | Nov 2, 2020
Politics, Policy & Law

‘Vaccinationalism’ could keep poor countries unprotected from pandemic

As the U.S. and Europe prepare mass vaccination plans for 2021, billions of people living in low- and middle-income countries could have to wait until 2024 for the chance to be protected from COVID-19,...
BioCentury | Jul 22, 2020
Finance

Shonan iPark venture consortium seeks to boost bets on Japanese biotechs

A consortium established by Japanese life sciences accelerator Shonan iPark aims to grow the funding base for local biotechs by bolstering connections between investors. The Japan VC Consortium, launched Tuesday, will promote collaboration between Japanese...
BioCentury | May 14, 2020
Management Tracks

Former GSK exec Slaoui to lead Trump’s ‘Warp Speed’ vaccine initiative

BIO President and CEO Jim Greenwood welcomed the appointment Wednesday of vaccine veteran Moncef Slaoui as head of the Trump administration’s Operation Warp Speed initiative, which is intended to fast-track COVID-19 vaccine development. Slaoui, now...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BioCentury | Apr 7, 2020
Product Development

Doing the right thing isn’t enough. The public needs to know

Now is not the time for the industry to be doing good behind closed doors. The biopharma industry has broken its norms in an all-hands-on-deck campaign to arrest the coronavirus crisis. It is shelving projects...
BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
BioCentury | Aug 31, 2019
Product Development

Digital dollars: financing for digital health

...others Mkt No Series A $2.5 AstraZeneca, Genentech Inc. , Merck & Co. Merck Global Health Innovations...
...Biomarker & tool Type II diabetes Mkt No IPO $408.5 Merck & Co. Merck Global Health Innovations...
...Series C $20.5 AbbVie Inc. (NASDAQ:ABBV), Biogen Inc. (NASDAQ:BIIB), undisclosed others Hikma Ventures, Merck Global Health Innovations...
BioCentury | Jul 26, 2019
Emerging Company Profile

Limbix: A virtual treatment for the reality of depression

Limbix is using virtual reality to treat mental health conditions, starting with adolescent depression, where it could offer an alternative to medicating kids and the long wait lists for therapists. The company launched in 2016...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
Items per page:
1 - 10 of 94